KRAS and non-small cell lung carcinoma: Galassi et al. (2024) [106] reported an in-depth study of gold(I/III)–NHC complexes on non-small-cell lung cancer (NSCLC) cell lines, with or without KRAS mutations (A549, H460, H1792, HCC-44, H1355, and H522, H661, H1395, H1993, respectively) to study the mechanism of action of the synthesized complexes.